Business Wire

nShift: Delivery Data Ensures Retailers Aren’t Left Empty Handed After Peak Season

Share

nShift, the global leader in delivery & experience management (DMXM), today highlights five ways retailers can unlock savings and additional revenues from the delivery experience in the run up to Black Friday and beyond.

Consumer confidence across Europe has recovered strongly during 2024.1 Yet pricing and discounts will remain the most important factors in purchasing decisions for most shoppers for this year’s Black Friday shopping bonanza.2 This will add to pressures on retailers to discount heavily throughout peak season, with knock-on impacts on profit margins.

Businesses can use data gathered throughout the delivery process to turn peak-season bargain hunters into loyal customers, while boosting the bottom line.

nShift’s guide, “Creating a data-driven delivery experience”, outlines five approaches for combining data from deliveries and sales to raise profits:

  1. Comparing and reducing carrier costs. Last-mile deliveries account for over half of all logistics costs – but these costs cannot always be recovered from customers. By comparing carrier rates and negotiating reductions, retailers can reduce their last-mile costs.
  2. Optimizing checkouts to improve conversions. As with payments, customers prefer to receive their items in different ways. For example, they may want signed-for deliveries for fragile items, or PUDO (out of home pick up/drop off locations) for clothing or cosmetics. Tailoring the checkout experience to reflect customer needs can enable retailers to increase conversions by up to 20%.
  3. Reducing profit erosion from returns. The right returns software ensures resaleable items can be swiftly returned to the shelves. And insights into the reasons for returns can help retailers improve product descriptions, so more customers “buy right first time” to minimize returns in future.
  4. Turning delivery tracking into additional sales opportunities – customers are more engaged with ecommerce brands while they wait for deliveries than at any other time in their journey. Those that can weave product promotions and offers into post-purchase communications and processes are more likely to benefit from repeat purchases and upselling.
  5. Building customer loyalty with great delivery experiences. 85% of shoppers will consider buying elsewhere after just one bad delivery experience. Armed with data on every delivery they make, retailers can press carrier partners for improvements, and ensure they keep their promises to customers.

Maarten Tops, product director enterprise at nShift, said: “In their quest to offer customers the best Black-Friday deals, many retailers will cut profit margins to the bone. But they can still contain costs and build efficiencies – and data gathered during the delivery process holds the keys.

“This data fills a key blind spot in the customer journey, enabling retailers to build a clear understanding of every stage, from the homepage to the doorstep. It enables them to go into the new year armed with insights that can help reduce costs, build loyalty, and drive operational efficiencies.”

nShift’s delivery and experience management (DMXM) suite is a unique combination of enterprise-class delivery management, a library of 1000+ carriers, and customer-facing applications. It provides a joined-up, end-to-end experience from the checkout to the doorstep.

Read the full report: “Creating a data-driven delivery experience: how delivery and experience management (DMXM) unlocks business-changing insights for online retailers”.

About nShift

nShift’s delivery & experience management (DMXM) platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

1https://economy-finance.ec.europa.eu/document/download/d0bc7d61-d91f-4c67-9c3c-a8b70a075db5_en?filename=Flash_consumer_2024_09_en.pdf
2https://www.klaviyo.com/uk/wp-content/uploads/sites/2/2024/09/2024-Black-Friday-shopping-trends-report.pdf

View source version on businesswire.com: https://www.businesswire.com/news/home/20241029474804/en/

Contacts

James Ellerington: James - James.Ellerington@fourteenforty.uk
.Ellerington@fourteenforty.uk - James.Ellerington@fourteenforty.uk / (+44) 07725
534941

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye